---
title: "IceCure Regains Compliance with Nasdaq Minimum Bid Price Requirement | ICCM Stock News"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290829935.md"
description: "IceCure Medical Ltd. (NASDAQ: ICCM) announced it has regained compliance with Nasdaq's minimum bid price requirement. The company received written notice from Nasdaq on June 18, 2026, confirming that its ordinary shares maintained a closing bid price of at least $1.00 for ten consecutive business days from June 4 to June 17, 2026. Consequently, the bid price deficiency matter is now closed."
datetime: "2026-06-25T04:12:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290829935.md)
  - [en](https://longbridge.com/en/news/290829935.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290829935.md)
---

# IceCure Regains Compliance with Nasdaq Minimum Bid Price Requirement | ICCM Stock News

, /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that on June 18, 2026, it received written notice from Nasdaq Stock Market LLC ("Nasdaq"), indicating that the Company has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00 per share.

The Nasdaq staff made this determination of compliance after the closing bid price of the Company's ordinary shares was $1.00 per share or greater for the 10 consecutive business days from June 4 to June 17, 2026. Accordingly, the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2) and Nasdaq considers the bid price deficiency matter now closed.

**About IceCure Medical**

IceCure Medical (NASDAQ: ICCM) develops and markets advanced liquid-nitrogen-based cryoablation therapy systems for the destruction of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology is a safe and effective option to surgical tumor removal that is easily performed in a relatively short procedure. The Company's flagship ProSense® system is marketed and sold worldwide for the indications cleared and approved to date including in the U.S., Europe and Asia.

**IR Contact:**

Email: investors@icecure-medical.com  
Meir Peleg, CFO  
Phone: +1-888-902-5716

Logo: https://mma.prnewswire.com/media/2319310/IceCure\_Medical\_Logo.jpg

SOURCE IceCure Medical

### Related Stocks

- [ICCM.US](https://longbridge.com/en/quote/ICCM.US.md)

## Related News & Research

- [IceCure Medical Kicks Off its Post-Marketing "ChoICE" Study for the Low-Risk Breast Cancer Treatment at First U.S Clinical Site | ICCM Stock News](https://longbridge.com/en/news/293933610.md)
- [J-Star Holding Co., Ltd Regains Compliance with Nasdaq Minimum Bid Price Requirement | YMAT Stock News](https://longbridge.com/en/news/294508620.md)
- [PowerCompute Regains Compliance with Nasdaq Minimum Bid Price Requirement | PWCM Stock News](https://longbridge.com/en/news/294179666.md)
- [Uni-Fuels Announces Receipt of Nasdaq Notification Letter Regarding Minimum Price Deficiency | UFG Stock News](https://longbridge.com/en/news/294556631.md)
- [SCWorx Receives Nasdaq Hearings Panel Partial Compliance Letter for the Company’s Continued Listing on the Nasdaq Capital Market | WORX Stock News](https://longbridge.com/en/news/294222493.md)